Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?
Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.
Is Nuvation Bio building the next IDH1 glioma contender with safusidenib and SIGMA?
Nuvation Bio now controls safusidenib globally. Read why the Japan deal matters for IDH1-mutant glioma, SIGMA, and the post-vorasidenib market.